SCIENTIFIC MEETINGS
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases by contributing to cutting-edge research. Below, you can find Dyne-sponsored posters, oral presentations, and symposia content from global congresses.
The FORCE™ platform, zeleciment-basivarsen (z-basivarsen, formerly known as DYNE-101), zeleciment-rostudirsen (z-rostudirsen, formerly known as DYNE-251), DYNE-302, and DYNE-401 are investigational or otherwise in development and have not been approved as safe or effective by the US FDA, EMA or any other regulatory authority.
